175 related articles for article (PubMed ID: 25499216)
1. Harnessing the p53-PUMA axis to overcome DNA damage resistance in renal cell carcinoma.
Zhou X; Tolstov Y; Arslan A; Roth W; Grüllich C; Pahernik S; Hohenfellner M; Duensing S
Neoplasia; 2014 Dec; 16(12):1028-35. PubMed ID: 25499216
[TBL] [Abstract][Full Text] [Related]
2. Wnt antagonist DKK1 acts as a tumor suppressor gene that induces apoptosis and inhibits proliferation in human renal cell carcinoma.
Hirata H; Hinoda Y; Nakajima K; Kawamoto K; Kikuno N; Ueno K; Yamamura S; Zaman MS; Khatri G; Chen Y; Saini S; Majid S; Deng G; Ishii N; Dahiya R
Int J Cancer; 2011 Apr; 128(8):1793-803. PubMed ID: 20549706
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance and expression of PUMA, MCL-1, and p53 in human renal cell carcinoma and para-carcinoma tissues.
Xia HB; Cui HW; Su L; Zhang ZH; Yang XY; Ning SQ; Su XL
Genet Mol Res; 2017 Jul; 16(3):. PubMed ID: 28692117
[TBL] [Abstract][Full Text] [Related]
4. Cisplatin induced apoptosis of ovarian cancer A2780s cells by activation of ERK/p53/PUMA signals.
Song H; Wei M; Liu W; Shen S; Li J; Wang L
Histol Histopathol; 2018 Jan; 33(1):73-79. PubMed ID: 28287251
[TBL] [Abstract][Full Text] [Related]
5. Deficient activation of CD95 (APO-1/Fas)-mediated apoptosis: a potential factor of multidrug resistance in human renal cell carcinoma.
Ramp U; Dejosez M; Mahotka C; Czarnotta B; Kalinski T; Wenzel M; Lorenz I; Müller M; Krammer P; Gabbert HE; Gerharz CD
Br J Cancer; 2000 Jun; 82(11):1851-9. PubMed ID: 10839301
[TBL] [Abstract][Full Text] [Related]
6. Loss of the tissue-specific proapoptotic BH3-only protein Nbk/Bik is a unifying feature of renal cell carcinoma.
Sturm I; Stephan C; Gillissen B; Siebert R; Janz M; Radetzki S; Jung K; Loening S; Dörken B; Daniel PT
Cell Death Differ; 2006 Apr; 13(4):619-27. PubMed ID: 16322756
[TBL] [Abstract][Full Text] [Related]
7. Frequent expression of Bcl-2 in renal-cell carcinomas carrying wild-type p53.
Tomita Y; Bilim V; Kawasaki T; Takahashi K; Okan I; Magnusson KP; Wiman KG
Int J Cancer; 1996 May; 66(3):322-5. PubMed ID: 8621251
[TBL] [Abstract][Full Text] [Related]
8. The role of apoptosis repressor with a CARD domain (ARC) in the therapeutic resistance of renal cell carcinoma (RCC): the crucial role of ARC in the inhibition of extrinsic and intrinsic apoptotic signalling.
Toth C; Funke S; Nitsche V; Liverts A; Zlachevska V; Gasis M; Wiek C; Hanenberg H; Mahotka C; Schirmacher P; Heikaus S
Cell Commun Signal; 2017 May; 15(1):16. PubMed ID: 28464919
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of Fas-mediated apoptosis in renal cell carcinoma cells by adriamycin.
Wu XX; Mizutani Y; Kakehi Y; Yoshida O; Ogawa O
Cancer Res; 2000 Jun; 60(11):2912-8. PubMed ID: 10850437
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic efficacy of PUMA for malignant glioma cells regardless of p53 status.
Ito H; Kanzawa T; Miyoshi T; Hirohata S; Kyo S; Iwamaru A; Aoki H; Kondo Y; Kondo S
Hum Gene Ther; 2005 Jun; 16(6):685-98. PubMed ID: 15960600
[TBL] [Abstract][Full Text] [Related]
11. Wnt antagonist DICKKOPF-3 (Dkk-3) induces apoptosis in human renal cell carcinoma.
Ueno K; Hirata H; Majid S; Chen Y; Zaman MS; Tabatabai ZL; Hinoda Y; Dahiya R
Mol Carcinog; 2011 Jun; 50(6):449-57. PubMed ID: 21268126
[TBL] [Abstract][Full Text] [Related]
12. Paclitaxel/Taxol sensitivity in human renal cell carcinoma is not determined by the p53 status.
Reinecke P; Kalinski T; Mahotka C; Schmitz M; Déjosez M; Gabbert HE; Gerharz CD
Cancer Lett; 2005 May; 222(2):165-71. PubMed ID: 15863265
[TBL] [Abstract][Full Text] [Related]
13. Topotecan (Hycamtin) responsiveness in human renal carcinoma cell lines of the clear cell and papillary types.
Ramp U; Mahotka C; Kalinski T; Ebel E; Gabbert HE; Gerharz CD
Anticancer Res; 2001; 21(5):3509-17. PubMed ID: 11848517
[TBL] [Abstract][Full Text] [Related]
14. Combined p53 and MDM2 biomarker analysis shows a unique pattern of expression associated with poor prognosis in patients with renal cell carcinoma undergoing radical nephrectomy.
Noon AP; Polański R; El-Fert AY; Kalirai H; Shawki H; Campbell F; Dodson A; Eccles RM; Lloyd BH; Sibson DR; Coupland SE; Lake SL; Parsons K; Vlatković N; Boyd MT
BJU Int; 2012 Apr; 109(8):1250-7. PubMed ID: 21756282
[TBL] [Abstract][Full Text] [Related]
15. p53 pathway in renal cell carcinoma is repressed by a dominant mechanism.
Gurova KV; Hill JE; Razorenova OV; Chumakov PM; Gudkov AV
Cancer Res; 2004 Mar; 64(6):1951-8. PubMed ID: 15026329
[TBL] [Abstract][Full Text] [Related]
16. Sensitivity to TRAIL/APO-2L-mediated apoptosis in human renal cell carcinomas and its enhancement by topotecan.
Déjosez M; Ramp U; Mahotka C; Krieg A; Walczak H; Gabbert HE; Gerharz CD
Cell Death Differ; 2000 Nov; 7(11):1127-36. PubMed ID: 11139287
[TBL] [Abstract][Full Text] [Related]
17. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F
Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971
[TBL] [Abstract][Full Text] [Related]
18. Mutant p53 drives cancer chemotherapy resistance due to loss of function on activating transcription of PUMA.
Huang Y; Liu N; Liu J; Liu Y; Zhang C; Long S; Luo G; Zhang L; Zhang Y
Cell Cycle; 2019 Dec; 18(24):3442-3455. PubMed ID: 31726940
[No Abstract] [Full Text] [Related]
19. Tumor suppressor activity and epigenetic inactivation of hepatocyte growth factor activator inhibitor type 2/SPINT2 in papillary and clear cell renal cell carcinoma.
Morris MR; Gentle D; Abdulrahman M; Maina EN; Gupta K; Banks RE; Wiesener MS; Kishida T; Yao M; Teh B; Latif F; Maher ER
Cancer Res; 2005 Jun; 65(11):4598-606. PubMed ID: 15930277
[TBL] [Abstract][Full Text] [Related]
20. Transcription factor Sox4 is required for PUMA-mediated apoptosis induced by histone deacetylase inhibitor, TSA.
Jang SM; Kang EJ; Kim JW; Kim CH; An JH; Choi KH
Biochem Biophys Res Commun; 2013 Aug; 438(2):445-51. PubMed ID: 23916609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
